晚期癌症相关疼痛合并阿片类药物误用或使用障碍的阿片类药物管理共识指南
该改良德尔菲共识研究邀请129名姑息治疗与成瘾医学专家,就3种临床场景评估阿片类药物管理策略的适当性。结果显示,对未经治疗的阿片类药物使用障碍患者,开始丁丙诺啡/纳洛酮治疗被认为适当,转诊美沙酮门诊则不适当;对超处方量使用阿片类药物的患者,加强监测适当,减量不适当。
要点
- 未经治疗的阿片类药物使用障碍患者,开始丁丙诺啡/纳洛酮适当,转诊美沙酮门诊不适当。
- 超处方量使用阿片类药物的患者,加强监测适当,减量不适当。
- 尿检非处方苯二氮䓬类阳性的患者,加强监测适当,减量及处方丁丙诺啡/纳洛酮不适当。
核心结论
- 该定性研究结果为临床医生提供了基于共识的指导,并强调了关键的研究和政策空白。
研究设计与样本
- 定性研究,采用ExpertLens在线平台和方法实施改良德尔菲小组,于2020年8月至10月开展2个改良德尔菲小组。
- 邀请129名姑息治疗或成瘾医学专家,120名参与至少1轮,84名参与全部3轮。
- 评估3种临床场景:未经治疗的阿片类药物使用障碍病史、超处方量使用阿片类药物、使用非处方苯二氮䓬类药物。
主要发现
- 参与者多为女性(47 [62%])、白人(94 [78 (65%)])、持有MD/DO学位(115 [96%])。
- 对未经治疗的阿片类药物使用障碍患者,无论预后如何,开始丁丙诺啡/纳洛酮治疗被认为适当,转诊美沙酮门诊被认为不适当。
- 开始分次剂量美沙酮对较短预后患者被认为适当,对较长预后患者适当性不确定。
- 开始全阿片受体激动剂对短预后患者适当性不确定,对较长预后患者被认为不适当。
- 对无阿片类药物使用障碍病史但超处方量使用阿片类药物的患者,无论预后如何,加强监测适当、减量不适当、增加阿片类药物或转换为丁丙诺啡/纳洛酮适当性不确定。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Opioid misuse and opioid use disorder (OUD) are important comorbidities in people with advanced cancer and cancer-related pain, but there is a lack of consensus on treatment. OBJECTIVE: To develop consensus among palliative care and addiction specialists on the appropriateness of various opioid management strategies in individuals with advanced cancer-related pain and opioid misuse or OUD. DESIGN, SETTING, AND PARTICIPANTS: For this qualitative study, using ExpertLens, an online platform and methodology for conducting modified Delphi panels, between August and October 2020, we conducted 2 modified Delphi panels to understand the perspectives of palliative and addiction clinicians on 3 common clinical scenarios varying by prognosis (weeks to months vs months to years). Of the 129 invited palliative or addiction medicine specialists, 120 participated in at least 1 round. A total of 84 participated in all 3 rounds. MAIN OUTCOMES AND MEASURES: Consensus was investigated for 3 clinical scenarios: (1) a patient with a history of an untreated opioid use disorder, (2) a patient taking more opioid than prescribed, and (3) a patient using nonprescribed benzodiazepines. RESULTS: Participants were mostly women (47 [62%]), White (94 (78 [65%]), and held MD/DO degrees (115 [96%]). For a patient with untreated OUD, regardless of prognosis, it was deemed appropriate to begin treatment with buprenorphine/naloxone and inappropriate to refer to a methadone clinic. Beginning split-dose methadone was deemed appropriate for patients with shorter prognoses and of uncertain appropriateness for those with longer prognoses. Beginning a full opioid agonist was deemed of uncertain appropriateness for those with a short prognosis and inappropriate for those with a longer prognosis. Regardless of prognosis, for a patient with no medical history of OUD taking more opioids than prescribed, it was deemed appropriate to increase monitoring, inappropriate to taper opioids, and of uncertain appropriateness to increase the patient's opioids or transition to buprenorphine/naloxone. For a patient with a urine drug test positive for non-prescribed benzodiazepines, regardless of prognosis, it was deemed appropriate to increase monitoring, inappropriate to taper opioids and prescribe buprenorphine/naloxone. CONCLUSIONS AND RELEVANCE: The findings of this qualitative study provide urgently needed consensus-based guidance for clinicians and highlight critical research and policy gaps.
引用
- Fitzgerald Jones K, Khodyakov D, Arnold R, et al. Consensus-Based Guidance on Opioid Management in Individuals With Advanced Cancer-Related Pain and Opioid Misuse or Use Disorder. JAMA Oncol. 2022. PMID: 35771550. doi:10.1001/jamaoncol.2022.2191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。